PNC Financial Services Group’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
PNC Financial Services Group's SABS Position: Q3 2026 in Review
PNC Financial Services Group held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 10,270 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3620.
PNC Financial Services Group first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $40.1K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- PNC Financial Services Group held 10,270 shares of SAB Biotherapeutics worth $32.6K as of Q3 2026.
- PNC Financial Services Group left its SAB Biotherapeutics share count unchanged in Q3 2026.
- SAB Biotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3620 holding.
- PNC Financial Services Group first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
- PNC Financial Services Group's SAB Biotherapeutics position peaked at $40.1K in Q2 2026.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.